Heska Co. (NASDAQ:HSKA) Expected to Post Quarterly Sales of $64.66 Million

Wall Street analysts expect Heska Co. (NASDAQ:HSKA) to post $64.66 million in sales for the current fiscal quarter, according to Zacks Investment Research. Two analysts have made estimates for Heska’s earnings. The highest sales estimate is $65.42 million and the lowest is $63.90 million. Heska reported sales of $56.64 million during the same quarter last year, which indicates a positive year over year growth rate of 14.2%. The company is scheduled to announce its next quarterly earnings results on Thursday, November 4th.

On average, analysts expect that Heska will report full year sales of $256.97 million for the current financial year, with estimates ranging from $255.30 million to $258.64 million. For the next fiscal year, analysts forecast that the company will post sales of $285.02 million, with estimates ranging from $276.10 million to $293.93 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side analysts that cover Heska.

Heska (NASDAQ:HSKA) last posted its quarterly earnings data on Tuesday, August 3rd. The medical research company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.13. The firm had revenue of $64.93 million during the quarter, compared to analysts’ expectations of $56.82 million. Heska had a negative net margin of 0.59% and a positive return on equity of 1.42%. The business’s revenue was up 42.0% compared to the same quarter last year.

Several equities research analysts have recently commented on the stock. Guggenheim upgraded shares of Heska from a “neutral” rating to a “buy” rating and set a $280.00 price target for the company in a research report on Monday, July 12th. Zacks Investment Research upgraded shares of Heska from a “hold” rating to a “buy” rating and set a $293.00 price target for the company in a research report on Wednesday, August 11th. Alliance Global Partners reiterated a “buy” rating and set a $310.00 price target (up previously from $240.00) on shares of Heska in a research report on Wednesday, August 4th. Finally, Piper Sandler lifted their price target on shares of Heska from $240.00 to $305.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 4th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Heska currently has an average rating of “Buy” and a consensus target price of $268.00.

In other Heska news, CFO Catherine Grassman sold 5,000 shares of Heska stock in a transaction that occurred on Friday, August 6th. The shares were sold at an average price of $260.24, for a total value of $1,301,200.00. Following the transaction, the chief financial officer now owns 8,986 shares of the company’s stock, valued at $2,338,516.64. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, COO Nancy Wisnewski sold 1,000 shares of Heska stock in a transaction that occurred on Wednesday, August 18th. The shares were sold at an average price of $270.33, for a total transaction of $270,330.00. Following the completion of the transaction, the chief operating officer now directly owns 55,499 shares in the company, valued at approximately $15,003,044.67. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 8,000 shares of company stock valued at $2,105,190. Corporate insiders own 8.60% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of HSKA. FMR LLC raised its position in Heska by 2.0% during the first quarter. FMR LLC now owns 453,664 shares of the medical research company’s stock worth $38,616,000 after acquiring an additional 8,870 shares in the last quarter. Comerica Bank raised its position in Heska by 6.8% during the first quarter. Comerica Bank now owns 9,899 shares of the medical research company’s stock worth $1,805,000 after acquiring an additional 631 shares in the last quarter. US Bancorp DE raised its position in Heska by 6.6% during the first quarter. US Bancorp DE now owns 3,423 shares of the medical research company’s stock worth $576,000 after acquiring an additional 211 shares in the last quarter. Texas Permanent School Fund raised its position in Heska by 3.6% during the first quarter. Texas Permanent School Fund now owns 7,393 shares of the medical research company’s stock worth $1,245,000 after acquiring an additional 257 shares in the last quarter. Finally, Victory Capital Management Inc. raised its position in Heska by 57.7% during the first quarter. Victory Capital Management Inc. now owns 6,698 shares of the medical research company’s stock worth $1,128,000 after acquiring an additional 2,450 shares in the last quarter. 94.92% of the stock is currently owned by hedge funds and other institutional investors.

HSKA traded up $3.36 during midday trading on Thursday, hitting $252.03. The company had a trading volume of 25,722 shares, compared to its average volume of 70,474. Heska has a twelve month low of $95.46 and a twelve month high of $275.94. The firm’s 50-day simple moving average is $257.81 and its 200-day simple moving average is $217.33. The company has a debt-to-equity ratio of 0.19, a quick ratio of 6.98 and a current ratio of 7.98. The company has a market capitalization of $2.68 billion, a PE ratio of -1,329.74 and a beta of 1.72.

About Heska

Heska Corp. engages in the provision of veterinary and animal health diagnostic, and specialty products. It operates through the North America and International segments. The North America segment includes the United States, Canada, and Mexico. The International segment involves Australia, France, Germany, Italy, Malaysia, Spain, and Switzerland.

Read More: Euro STOXX 50 Index

Get a free copy of the Zacks research report on Heska (HSKA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.